DarioHealth Corp.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsDarioHealth Corp. is a vertically integrated digital health platform delivering chronic care management through FDA-cleared devices, AI, and coaching.
What they do
DarioHealth owns a full chain of value in chronic care: connected FDA-cleared hardware, AI built on proprietary data, and a behavior-change coaching layer validated by over 100 peer-reviewed studies. Its whole-person platform addresses diabetes, hypertension, pre-diabetes, musculoskeletal (MSK), and behavioral health. It sells primarily to employers, health plans, pharmaceutical companies, and providers, with roots in direct-to-consumer (D2C) sales.
Revenue drivers
- B2B2C contracts — More than 100 signed contracts with providers, employers, health plans, and pharma; primary channel for scaling.
- Direct-to-consumer (D2C) subscriptions — Historical sandbox for innovation; consumers pay out-of-pocket, driving engagement and clinical validation.
- Therapeutic area programs — Revenue tied to deployment across diabetes, hypertension, pre-diabetes, MSK, and behavioral health, each with recurring monitoring and coaching services.
Recent performance
Revenue has been roughly flat: Q3 2025 $5.0M, Q4 2025 $5.2M, Q1 2026 $5.6M, Q2 2026 $5.2M. Full-year 2025 revenue was $22.4M, down from $27.0M in 2024. Net loss narrowed from $-42.7M in 2024 to $-41.7M in 2025; operating cash flow improved to $-25.9M. Cash and equivalents fell to $6.6M at June 30, 2026, from $21.8M at year-end 2025.
Strategy
Management intends to rapidly scale the B2B2C model, building on over 100 signed contracts. They continue to use the D2C market as a laboratory for engagement and outcomes. Acquisitions (Upright, PsyInnovations, Physimax, Twill) are integrated to broaden the platform. Strategy centers on AI-driven personalization and whole-person, integrated physical and mental health solutions.
Risks
- Capital requirements — Limited revenue and negative cash flow require additional financing, which may cause dilution or restrictions; management estimates only 12 months of runway from the 10-K date.
- Cash burn — Cash fell to $6.6M at June 30, 2026, while operating cash flow remains negative (-$25.9M in 2025).
- Geopolitical exposure — Operations in Israel face risks from armed conflict and regional unrest, which could disrupt business.
- Debt facility compliance — The company has $31.1M long-term debt and must meet covenants; failure could accelerate repayment.
Outlook
Management believes current resources sustain operations for at least 12 months from the 10-K issuance, assuming commercial sales targets are met. They plan to continue scaling B2B2C and expand product deployments. Additional capital will likely be needed for working capital and growth.